

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF “DOXOFYLLINE GLUCOSE FOR INJECTION” AND “DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION”

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Doxofylline Glucose for Injection” and “Doxofylline Sodium Chloride for Injection” developed by the Group have been granted drug registration approval by the China Food and Drug Administration of the People’s Republic of China.

Doxofylline, a methylxanthine derivative, is a new type of xanthine drug different from the theophylline drug. Doxofylline can relax smooth muscles and is clinically used for the treatment of shortness of breath caused by bronchial asthma and chronic obstructive pulmonary disease. Compared with conventional drugs such as theophylline and aminophylline, doxofylline has demonstrated improved efficacy, decreased toxicity and rapid effect. It will not cause addiction or have impact on the central nervous system, gastrointestinal tract and cardiac functions. It also has advantages over aminophylline in terms of lowering heart rate, improving airflow and reducing airway reactions.

Products of doxofylline for injection are already available in both domestic and international markets. The doxofylline developed by the Group is in the form of large-volume injections. It can be clinically administered by intravenous infusion directly without the risk of potential contamination during preparation of small-volume infusion solutions, enabling a safer and more convenient clinical use. Among all forms of doxofylline, injection is predominant with enormous market share. The doxofylline for injection developed by the Company will be able to satisfy the clinical needs of patients and generate good returns.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 10 May 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Zhenguo, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors